CME

Program Description:

Taxane-based chemotherapy combined with lapatinib results in shorter progression-free survival (PFS) than with trastuzumab as first-line treatment for patients with HER2+ metastatic breast cancer, according to an interim analysis of an open-label phase 3 randomized study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.


Continue Reading

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with breast cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Identify patients whose tumors overexpress HER2 and who have received prior therapy, including EGFR- and HER2 receptor tyrosine kinases.
  • Assess first-line treatment for patients with HER2+ metastatic breast cancer based on recently released randomized controlled trials.

Click Next to begin the activity.